Updated Friday, Dec. 12, 2025.
Pfizer (NYSE: PFE) heads into the final full trading week before the holidays with a familiar mix of catalysts: pipeline updates that support its post‑COVID growth narrative, dealmaking in the red‑hot obesity space, and renewed regulatory headlines around COVID‑19 vaccines. Add in a freshly declared quarterly dividend and an upcoming 2026 guidance call, and Pfizer stock is setting up for another headline-driven stretch.
As of Friday’s close, Pfizer shares finished at $25.85 (up about 0.19% on the day), after trading between $25.72 and $26.04, with volume around 23 million shares.
What moved Pfizer stock this week: the biggest headlines investors tracked
1) Pfizer strikes a new obesity/GLP‑1 deal — and signals combo ambitions
Pfizer announced an exclusive global collaboration and license agreement with YaoPharma (a subsidiary of Shanghai Fosun Pharmaceutical) for YP05002, an oral small‑molecule GLP‑1 receptor agonist currently in Phase 1 development for chronic weight management.
Key deal terms Pfizer disclosed:
- $150 million upfront
- Up to $1.935 billion in development, regulatory, and commercial milestones
- Tiered royalties on sales if approved
Why it matters for PFE: Pfizer has been trying to rebuild credibility in obesity after prior internal GLP‑1 setbacks. This agreement also wasn’t positioned as a “one‑and‑done” asset purchase — Pfizer explicitly said it plans to test YP05002 in combination with its GIPR antagonist PF‑07976016 (currently Phase 2) and potentially with other small molecules. Pfizer
2) Tukysa posts stronger first‑line maintenance data in HER2+ metastatic breast cancer
Pfizer delivered one of the week’s most investor‑relevant pipeline updates: detailed Phase 3 HER2CLIMB‑05 results for TUKYSA (tucatinib) as part of an investigational first‑line maintenance combination (after chemo-based induction) in HER2+ metastatic breast cancer.
Highlights Pfizer reported:
- 35.9% reduction in risk of disease progression or death (HR 0.641, p<0.0001)
- Median progression‑free survival (PFS) of 24.9 months vs 16.3 months — an 8.6‑month improvement
This type of readout is the kind of “pipeline proof point” Pfizer bulls want to see as the company shifts attention from pandemic-era revenue toward oncology scale (including its Seagen acquisition) and late‑stage assets with expansion potential.
3) HYMPAVZI data targets a high-need hemophilia segment
Pfizer also highlighted Phase 3 BASIS results for HYMPAVZI (marstacimab) in adults and adolescents with hemophilia A or B with inhibitors, a segment with meaningful unmet need.
Pfizer reported a 93% reduction in treated annualized bleeding rate vs on‑demand bypassing agents, and said it has submitted the data to the FDA and EMA for review.
4) Dividend declared: $0.43 per share, payable March 6, 2026
On Dec. 12, Pfizer announced its board declared a $0.43 dividend for the first quarter of 2026, payable March 6, 2026, to shareholders of record as of Jan. 23, 2026. Pfizer noted this will be its 349th consecutive quarterly dividend.
At Friday’s closing price, that quarterly dividend implies an annualized payout of $1.72 and a yield of about 6.6% (based on price and annualizing the quarterly dividend).
Other late-week pressures: cost cuts, court news, and vaccine headlines
Switzerland job cuts underscore Pfizer’s ongoing restructuring
Reuters reported Pfizer will cut 200+ jobs in Switzerland, reducing the workforce there to roughly 70 by year‑end from about 300, as part of its multi‑year cost program.
The cost-cutting push is not new, but the continued “drip” of restructuring headlines can matter for sentiment: it reinforces Pfizer’s focus on protecting margins while it works to re-accelerate growth outside COVID products. Reuters+1
Seagen’s Enhertu patent win reversed on appeal
In a legal development tied to Pfizer’s oncology footprint, Reuters reported a U.S. appeals court overturned a nearly $42 million jury verdict Seagen (now Pfizer-owned) had won against Daiichi Sankyo and AstraZeneca over the blockbuster cancer drug Enhertu, saying the patent at issue was invalid.
COVID‑19 vaccine scrutiny returns to the headlines
A separate Reuters report said the FDA intends to place a boxed (“black box”) warning on COVID‑19 vaccines, citing a CNN report and noting the plan was not finalized and could change. Pfizer reiterated that its vaccine continues to show a favorable safety and efficacy profile supported by extensive real‑world evidence. Reuters
Reuters also reported the U.S. health regulator is investigating deaths potentially related to COVID‑19 vaccines across multiple age groups as part of a safety review.
For Pfizer stock, this is a classic “headline risk” item: even if it doesn’t change financial forecasts overnight, it can swing near‑term sentiment given Pfizer’s continued (though reduced) exposure to COVID‑19 vaccine economics and policy decisions.
Wall Street forecasts: where analysts stand on Pfizer stock right now
Analyst views on Pfizer remain mixed — often reflecting the same debate investors have been having for two years: Is PFE primarily a high‑yield value stock with cost‑cut support, or a pipeline turnaround story that still has execution risk?
A few notable updates circulating this week:
- Morgan Stanley lowered its Pfizer price target to $28 from $32, keeping an Equal Weight rating, according to TheFly via TipRanks.
- BMO Capital reiterated an Outperform rating with a $30 price target after the tucatinib (Tukysa) data, according to StreetInsider.
- Guggenheim previously raised its price target to $35 from $33 and kept a Buy rating in late November, per TheFly via TipRanks.
What’s consistent across many notes: analysts want cleaner visibility into the post‑COVID earnings base and more confidence that Pfizer’s newer growth bets (oncology expansion, obesity pipeline rebuild, rare disease franchises) can offset pricing pressures and loss‑of‑exclusivity risks over time.
The fundamentals backdrop: what Pfizer has guided so far
While investors now focus on 2026, the most recent official guideposts still come from Pfizer’s Q3 reporting:
In its third‑quarter 2025 results, Pfizer:
- Reaffirmed 2025 revenue guidance of $61.0 to $64.0 billion
- Raised and narrowed 2025 adjusted diluted EPS guidance to $3.00 to $3.15
- Pointed to cost improvement initiatives targeting ~$7.2 billion in anticipated net savings by the end of 2027 (as previously announced)
The company also described continued pressure from declining COVID‑product demand, tied to lower infection rates and narrower U.S. vaccine recommendations.
Week ahead: the key catalyst for Pfizer stock (Dec. 15–19, 2025)
Pfizer’s 2026 guidance call: Tuesday, Dec. 16 at 8:00 a.m. ET
The most important scheduled event for PFE next week is Pfizer’s conference call with analysts on Dec. 16 to provide full‑year 2026 financial guidance.
What investors will likely listen for:
- 2026 revenue and EPS ranges (and how management frames growth vs. cost-cut contribution)
- Updates on the multi‑year cost program and what’s “one‑time” versus sustainable savings
- Commentary on oncology momentum (including how assets like Tukysa fit into broader strategy)
- How Pfizer describes its obesity pipeline roadmap following the YaoPharma GLP‑1 deal
- Capital allocation tone: dividend posture (now reaffirmed) vs. any signals on buybacks
Ongoing “headline watch” items
Even without major scheduled FDA decisions next week, Pfizer investors may also track:
- Any updates on the FDA’s vaccine safety review and the reported boxed-warning plan
- U.S.–China biotech policy developments (including legislation that could shape future cross-border biotech collaboration)
Bottom line for Pfizer stock heading into next week
Pfizer enters the week ahead with a tangible near-term catalyst — 2026 guidance on Dec. 16 — and a news cycle that’s been unusually dense for a traditionally “defensive” pharma name. Pfizer
The bullish argument is getting fresh support from pipeline updates (Tukysa, HYMPAVZI) and strategic moves to rebuild an obesity platform, while the bearish case points to continued uncertainty around policy, vaccine headlines, and the need for sustained execution beyond cost cutting.
